#United States #Orlando #Alcanza #Karim Chalhoub #Jeff Irving

Alcanza Clinical Research Strengthens Leadership Team

Alcanza Clinical Research, a dedicated network for clinical investigation, has made significant strides in its leadership by appointing Karim Chalhoub as the President and Chief Operating Officer, alongside Jeff Irving as the Chief Financial Officer. These appointments are reflective of Alcanza's commitment to strategic growth while improving participation in clinical research.

Leadership Appointments

Karim Chalhoub, now at the helm as President and COO, will direct all operational aspects of Alcanza, emphasizing the establishment of high-performance teams and elevating patient experience. With a robust background spanning over two decades in healthcare, Karim has an impressive track record in multi-site clinical operations, consistently aiming for improved patient outcomes. Before his role at Alcanza, he served as COO at Caravel Autism Health, where his leadership significantly enhanced operational protocols and care delivery through advanced technology.

Jeff Irving brings a wealth of financial expertise as the new CFO of Alcanza. With 25 years in the sector, he is tasked with overseeing budgeting, forecasts, and ensuring financial compliance across the network. Irving's well-established history in healthcare finance, including significant positions at OMS360 and Banfield Pet Hospital, has been pivotal in developing acquisition strategies and achieving organic growth.

Vision for the Future

Alcanza Clinical Research is on a mission to minimize barriers to clinical trial participation. The integrated network consists of 24 specialized research units, supplemented by additional clinics throughout the southeastern, northeastern, and midwestern regions of the United States, as well as Puerto Rico. Under his new leadership, the focus will continue on enhancing access for underrepresented patient populations.

Carlos Orantes, CEO of Alcanza, expressed optimism regarding Chalhoub's and Irving's capabilities, stating, "The extensive experiences that Jeff and Karim bring will significantly enhance Alcanza's vision of expanded access to clinical research and improvement in patient care. I am eager to collaborate with them as we grow as a pioneering entity within clinical research."

In summary, these strategic leadership appointments underscore Alcanza’s dedication to not just growth in numbers, but in its ability to conduct patient-centered clinical research that is accessible to a wider audience. Both Chalhoub and Irving are expected to bring transformative changes that align with their shared goals of improving healthcare outcomes through innovative research practices. The ongoing evolution of Alcanza as a leader in clinical research is set to benefit the healthcare industry significantly.